Want to see MED full AI Analyst Report?
MED Stock Chart & Stats
$9.68
$0.23(2.38%)
At close: 4:00 PM EDT
$9.68
$0.23(2.38%)
Day’s Range― - ―
52-Week Range$9.22 - $14.67
Previous Close$9.91
Volume152.25K
Average Volume (3M)183.09K
Market Cap
$134.17M
Enterprise Value-$24.06
Total Cash (Recent Filing)$169.82M
Total Debt (Recent Filing)$27.62M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 09, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding11,180,703
10 Day Avg. Volume175,854
30 Day Avg. Volume183,095
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.30
P/FCF Ratio93.90
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.00Price Target Upside23.97% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.85
Revenue Forecast (FY)$279.70M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Minimal Financial LeverageSubstantial liquidity and no debt provide flexibility to fund product development, brand investment, restructuring and other recovery initiatives while reducing balance-sheet risk during the turnaround.
Improving Coach Productivity And Strategic Product RepositioningHigher productivity indicates stronger economics among remaining coaches, while the Trilivy repositioning and new product platform could broaden the offer and support customer relevance in metabolic health.
High Gross Margin And Active Cost-reduction ProgramHigh gross margins preserve attractive product economics, while lower SG&A and facility, technology and efficiency actions create a path to better operating leverage if revenue stabilizes.
Bears Say
Severe And Persistent Revenue ContractionThe prolonged top-line decline reduces scale, weakens fixed-cost absorption and limits reinvestment capacity. Recovery depends on the rebrand, products and coach model reversing a substantial loss of demand.
Shrinking Active Coach NetworkThe coach network is central to customer acquisition and repeat purchases, so sustained attrition threatens distribution capacity and recurring revenue. Productivity gains may not fully offset the loss of network scale.
Loss-making Operations And Weaker Cash GenerationOperating losses and compressed cash generation indicate that current volume is insufficient to support the cost base. Continued losses could consume liquidity and make the profitability target dependent on successful execution.
Medifast News
MED FAQ
What was Medifast Inc’s price range in the past 12 months?
Medifast Inc lowest stock price was $9.22 and its highest was $14.67 in the past 12 months.
What is Medifast Inc’s market cap?
Medifast Inc’s market cap is $134.17M.
When is Medifast Inc’s upcoming earnings report date?
Medifast Inc’s upcoming earnings report date is Nov 09, 2026 which is in 75 days.
How were Medifast Inc’s earnings last quarter?
Medifast Inc released its earnings results on Aug 03, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.65 by $0.37.
Is Medifast Inc overvalued?
According to Wall Street analysts Medifast Inc’s price is currently Undervalued.
Does Medifast Inc pay dividends?
Medifast Inc pays a Quarterly dividend of $1.65 which represents an annual dividend yield of N/A. See more information on Medifast Inc dividends here
What is Medifast Inc’s EPS estimate?
Medifast Inc’s EPS estimate is -0.35.
How many shares outstanding does Medifast Inc have?
Medifast Inc has 11,180,703 shares outstanding.
What happened to Medifast Inc’s price movement after its last earnings report?
Medifast Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.65. Following the earnings report the stock price went up 34.292%.
Which hedge fund is a major shareholder of Medifast Inc?
Currently, no hedge funds are holding shares in MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (23.97% Upside)
$12.00 (23.97% Upside)
Blogger Sentiment
Bullish
MED Sentiment 100%
Sector Average 55%
Sector Average 55%
Hedge Fund Trend
Decreased
By 294.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $894.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.32%
Trailing 12-Months
Company Description
Medifast Inc
Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region. Their extensive portfolio encompasses snack bars, savory bites, cereals, drinks, substantial meal choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, baked goods, and soups. These offerings are marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. The company facilitates sales primarily through direct e-commerce transactions. Established in 1980, Medifast, Inc. maintains its corporate headquarters in Baltimore, Maryland.
MED Company Deck
MED Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: materially negative near-term operating and top-line trends (notably a 27.6% revenue decline and a 48.7% drop in active coaches) contrast with strong strategic initiatives, improving coach productivity (+41% YoY), a healthy balance sheet ($169.8M cash, no debt), and targeted cost actions (Catalyst) with a goal to return to profitability in Q4 2026. Management emphasized structural steps (new Trilivy brand, scientific institute, compensation changes and training) that could drive medium-term recovery, but sizable current financial pressures and near-term uncertainty remain.View all MED earnings summariesMED Stock 12 Month Forecast
Average Price Target
$12.00
▲(23.97% Upside)
Technical Analysis
Ownership Overview
5.33% Insiders
14.51% Mutual Funds
16.69% Other Institutional Investors
49.61% Public Companies and
Individual Investors